Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Eli Lilly $1 billion notes offering
Davis Polk advised the joint book-running managers in connection with a registered offering by Eli Lilly and Company of $1.0…
NeoGenomics $300 million offerings of stock and convertible senior notes
Davis Polk advised the joint book-running managers in connection with concurrent SEC-registered offerings by…
Envision Healthcare $106 million exchange offer
Davis Polk advised the dealer manager in connection with the private offer by Envision Healthcare Corporation to exchange…
Aeglea BioTherapeutics $138 million stock and pre-funded warrants offering
Davis Polk advised the joint book-running managers in connection with a $138 million SEC-registered common stock and…
Biogen $3 billion senior notes offering
Davis Polk advised the representatives of the underwriters, in connection with the SEC-registered offering by Biogen Inc. of…
Akeso HK$2.44 billion IPO
Davis Polk advised the underwriters in the initial public offering and listing on the Hong Kong Stock Exchange and the…
Coherus BioSciences $200 million convertible notes offering
Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Coherus…
Natera $287.5 million convertible senior notes offering
Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Natera, Inc…
Nevro $346 million concurrent offerings of stock and convertible senior notes
Davis Polk advised the sole book-running manager in connection with the SEC-registered offering by Nevro Corp. of $189…
InnoCare Pharma HK$2.24 billion IPO
Davis Polk advised InnoCare Pharma Limited in connection with its initial public offering and listing on the Hong Kong Stock…